R&D In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Motavizumab reduced hospitalization in Phase III trial: MedImmune's motavizumab reduced hospitalizations due to respiratory syncytial virus by 83 percent compared to placebo in a Phase III trial, the firm says May 4. The monoclonal antibody is being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. The trial showed a 71 percent reduction in the incidence of RSV-specific lower respiratory infections requiring outpatient management, which was the study's secondary endpoint. The randomized, double-blind study involved 1,410 full-term healthy infants less than six months old in certain Southwest Native American populations and was designed to compare monthly intramuscular injections of motavizumab against placebo. The study confirmed what previous epidemiological studies have shown: that these populations have high rates of hospitalization due to RSV. Motavizumab would be a follow-on to AstraZeneca's Synagis (palivizumab)
You may also be interested in...
Bristol/Medarex Ipilimumab Toxicity Signals Efficacy, Investigator Says
The immune response side effects of ipilimumab serve as an efficacy signal for the melanoma therapy, according to one of the lead investigators studying the Bristol-Myers Squibb/Medarex immunotherapeutic
Weak Results Stop Pfizer's Tremelimumab Phase III Trial; Bristol Keeps Going
Pfizer discontinues single-agent trial of the CTLA-4 inhibitor in advanced melanoma, but Bristol-Myers Squibb announced it is still moving forward with its CTLA-4 inhibitor ipilimumab, which also failed a monotherapy melanoma trial
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011